Presentation Title

The Extraction and Analysis of Antimicrobial Secondary Metabolites Produced By Cave Streptomyces S1, S4, and PM58b

Format of Presentation

Poster to be presented Friday March 31, 2017

Abstract

Antibiotic resistance is a growing problem as microorganisms resistant even to those antibiotics of last resort have been discovered in hospitals around the world. Thus, it is necessary to develop new responses to resistant pathogens through the development of novel antibacterial compounds. A rich reservoir of antimicrobial compounds are microbial secondary metabolites which are molecules produced in response to changing environmental conditions providing some advantage to their producers. Particularly prolific producers of these compounds are bacteria of the group Streptomyces, which are responsible for a large portion of the naturally sourced antibacterial compounds used today. In order to access novel and untapped chemical diversity, the investigation of unexplored biological niches has become more prevalent, with the study of cave dwelling microorganisms producing promising leads. This study examines the antimicrobial secondary metabolites produced by three cave Streptomyces strains S1, S4, and PM58b for their previously described activity against target multi-drug resistant Escherichia coli and methicillin resistant Staphylococcus aureus with the goal of determining their molecular characteristics. The three strains of Streptomyces were grown at 15°C in R2A, V8, and Hickey Tresnar growth media shaking at 100rpm for a period of ten days to induce fermentative conditions and bioactivity was confirmed by agar-plug assay. Following this, these antimicrobial compounds will be extracted and characterized by mass spectrometry with the goal of initiating the structural elucidation of these compounds by the determination of their molecular masses and formulae.

Department

Biological Sciences

Faculty Advisor

Naowarat Cheeptham

This document is currently not available here.

Share

COinS
 

The Extraction and Analysis of Antimicrobial Secondary Metabolites Produced By Cave Streptomyces S1, S4, and PM58b

Antibiotic resistance is a growing problem as microorganisms resistant even to those antibiotics of last resort have been discovered in hospitals around the world. Thus, it is necessary to develop new responses to resistant pathogens through the development of novel antibacterial compounds. A rich reservoir of antimicrobial compounds are microbial secondary metabolites which are molecules produced in response to changing environmental conditions providing some advantage to their producers. Particularly prolific producers of these compounds are bacteria of the group Streptomyces, which are responsible for a large portion of the naturally sourced antibacterial compounds used today. In order to access novel and untapped chemical diversity, the investigation of unexplored biological niches has become more prevalent, with the study of cave dwelling microorganisms producing promising leads. This study examines the antimicrobial secondary metabolites produced by three cave Streptomyces strains S1, S4, and PM58b for their previously described activity against target multi-drug resistant Escherichia coli and methicillin resistant Staphylococcus aureus with the goal of determining their molecular characteristics. The three strains of Streptomyces were grown at 15°C in R2A, V8, and Hickey Tresnar growth media shaking at 100rpm for a period of ten days to induce fermentative conditions and bioactivity was confirmed by agar-plug assay. Following this, these antimicrobial compounds will be extracted and characterized by mass spectrometry with the goal of initiating the structural elucidation of these compounds by the determination of their molecular masses and formulae.